OmniAb unveils OmniUltra in vivo platform at TIDES USA event

OmniAb unveils OmniUltra in vivo platform at TIDES USA event
OmniAb launches OmniUltra platform

OmniAb announced the introduction of OmniUltra, its dual modality in vivo discovery platform, during the TIDES USA event in Boston this week.

The OmniUltra platform is designed to enhance the discovery of novel human antibodies and peptides, aiming to accelerate innovation in therapeutic research. The event brings together industry leaders focused on advancing biologics and peptide therapeutics, and OmniAb is connecting with attendees to share information on its latest technology.

OmniAb previously presented the OmniUltra dual-modality in vivo discovery platform for antibodies and peptides at the 2026 PEGS Summit. The platform focuses on facilitating human antibody and peptide discovery. Its recent debut at TIDES USA continues the company's engagement with key industry events.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.